<DOC>
	<DOCNO>NCT00854087</DOCNO>
	<brief_summary>Current treatment chronic liver disease rely upon remove primary insult liver ( e.g. , alcohol ) treat underlie viral infection ( HBV , HCV , etc. ) . However , case hepatitis C , significant number individual clear virus current approve standard antiviral therapy , leave option manage hepatic fibrosis , progress cirrhosis ultimately hepatocellular carcinoma ( HCC ) . Fuzheng Huayu use numerous study China find satisfactory prophylaxis effect chronic liver injury form liver fibrosis rat human . In addition , enhance degradation liver fibrosis protect hepatocytes injury death , manifest decrease ALT AST , enhancement albumin level . In addition , preliminary study indicate Fuzheng Huayu good safety tolerability profile promise efficacy . The number patient fail Interferon base therapy ( i.e . achieve SVR ) increase . There approved standard care treatment option population patient intolerant unwilling receive Interferon ; thus high risk progression fibrosis . Moreover , approve therapy treat hepatic fibrosis , basic research explore pathophysiological mechanism . Fuzheng Huayu easy administer , good safety efficacy profile fibrosis . Therefore , investigator propose study safety efficacy profile Fuzheng Huayu randomize , placebo-controlled , double blind study Chronic Hepatitis C patient hepatic fibrosis fail prior anti-HCV therapy intolerant refuse Interferon base therapy . The primary objective study establish safety efficacy Fuzheng Huayu treatment chronic hepatitis C subject fail prior anti-HCV therapy receive refuse Interferon base therapy improve liver fibrosis .</brief_summary>
	<brief_title>Assess Antifibrotic Activity Fuzheng Huayu Chronic Hepatitis C Patients With Hepatic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Main 1 . Male female 1870 year age . 2 . Chronic hepatitis C infection base documented history positive serum antiHCV antibody test and/or detectable level HCV RNA â‰¥ 50 IU/mL . 3 . Failure achieve sustain Virologic response ( SVR ) previous Interferon base therapy subject refuse Interferon base therapy intolerant Interferon . 4 . All subject enrol study fertile potentially fertile sexual partner subject must use two reliable form effective contraception study unless study participant/partner surgically sterile postmenopausal . Main 1 . Subjects history decompensated liver disease , include restrict portal hypertension manifest gastroesophageal varix , variceal bleeding , ascites , encephalopathy hepatic mass lesion suspicious hepatocellular carcinoma ( HCC ) . 2 . Liver histology consistent coexisting cause chronic liver disease ( apart fatty liver ) . 3 . Subjects treat HCV infection within 6 month Screening . 4 . Subjects experimental protocol therapy within 28 day Screening . 5 . Known HIV infection . 6 . Chronic hepatitis B infection 7 . Uncontrolled diabetes . 8 . Unstable uncontrolled thyroid disease 9 . Uncontrolled seizure disorder . 10 . History malignant cancer within last 5 year exception localize basal squamous cell carcinoma . 11 . Alcohol and/or drug abuse within past year . 12 . Pregnant lactate woman woman plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HCV</keyword>
	<keyword>Herbal treatment</keyword>
	<keyword>Herbs</keyword>
	<keyword>San Diego</keyword>
	<keyword>Non responder</keyword>
	<keyword>Relapser</keyword>
	<keyword>Treatment failure</keyword>
	<keyword>Antifibrotic</keyword>
	<keyword>Anti-fibrotic</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Failure previous Interferon base therapy</keyword>
	<keyword>Refuse Interferon base therapy</keyword>
	<keyword>Intolerance Interferon</keyword>
	<keyword>Male female 18-70 year age</keyword>
</DOC>